CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 160 enrolled
Drug / intervention
Cymbalta +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03271151
NCT03271151Phase 4Completed

Effect of Duloxetine on Opioid Use After Total Knee Arthroplasty: A Double-blinded Randomized Control Trial

Hospital for Special Surgery, New York·interventional·Posted Sep 1, 2017·Updated Dec 27, 2024

In Brief

A Phase 4 clinical trial evaluating Cymbalta and Placebo for Joint Disease and 2 related conditions. Completed, enrolled 160 participants across 1 site.

Detailed Summary

Post-discharge pain after total knee arthroplasty remains problematic; many patients have excessive pain at the 2 week time point (and often thereafter). Reduction in opioid use has become a national goal, due to the 'epidemic' in opioid misuse. In addition to enrolling non-opioid users, we will enroll up to 15 chronic opioid users.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201820192020202120222023202420252026
First PostedSep 1, 2017
Enrollment StartSep 28, 2017
Primary CompletionDec 3, 2020
Study CompletionFeb 19, 2021
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.8 years ago

Interventions

Cymbaltadrug

Duloxetine ("Cymbalta") is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain

Placeboother

Placebo to compare outcomes against Duloxetine